SPARC and neoplasm: Targeting nab-paclitaxel to the tumor site was hypothesized to depend on the binding of the albumin-moieties to the protein Secreted Protein Acidic and Rich in Cysteine (SPARC/osteonectin/BM40) overexpressed by fibroblasts in the stromal compartment [20].